Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone

Transplant International

Volumn 14, Issue 2, 2001, Pages 99-102

  Ter Meulen, Cornelis G ^a   Smak Gregoor, Peter J H ^b   Weimar, Willem ^b   Hilbrands, Luuk B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute rejection; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035038465     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001470050854     Document Type: Article

References (17)

1. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for the prevention of acute rejection
3. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial
4. Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone
5. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after renal transplantation
6. Effects of azathioprine withdrawal in kidney recipients with stable function two years after transplant
7. Kaposi's sarcoma after renal transplantation - Disappearance after reduction of immunosuppression and reappearance 7 years later after start of mycophenolate mofetil treatment
8. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis
9. Elective cyclosporine withdrawal after renal transplantation: A meta-analysis
10. The role of adaptation in allograft acceptance
11. A blinded, longterm, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
12. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation
13. Posttransplant malignancies
14. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients
15. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
16. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
17. Mycophenolate mofetil in cadaveric renal transplantation